CYP2D6 METABOLIZER PHENOTYPE PREDICTS ARIPIPRAZOLE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS

被引：0
|
作者：
Hiken, Eliah J. [1 ]
Poweleit, Ethan A. [1 ]
Keane, Corey [1 ]
Desta, Zeruesenay [1 ]
Strawn, Jeffrey R. [1 ]
Ramsey, Laura B.
机构：
[1] Univ Cincinnati, Cincinnati, OH USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY | 2023年 / 62卷 / 10期
关键词：
D O I：
10.1016/j.jaac.2023.09.140
中图分类号：
B844 [发展心理学（人类心理学）];
学科分类号：
040202 ;
摘要：
2.53
引用
收藏
页码：S197 / S197
页数：1
相关论文
共 50 条
  • [1] A Meta-Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics
    Blake, C. M.
    Kharasch, E. D.
    Schwab, M.
    Nagele, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (03) : 394 - 399
  • [2] Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response
    Sowinski, KM
    Burlew, BS
    PHARMACOTHERAPY, 1997, 17 (06): : 1305 - 1310
  • [3] CYP2C19 METABOLIZER PHENOTYPE PREDICTS SERTRALINE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS
    Poweleit, Ethan
    Vaughn, Samuel
    Desta, Zeruesenay
    Strawn, Jeffrey
    Ramsey, Laura
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 51 : E132 - E132
  • [4] Serum Concentrations of Risperidone and Aripiprazole in Subgroups Encoding CYP2D6 Intermediate Metabolizer Phenotype
    Hendset, Magnhild
    Molden, Espen
    Knape, Magnus
    Hermann, Monica
    THERAPEUTIC DRUG MONITORING, 2014, 36 (01) : 80 - 85
  • [5] CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD
    Trzepacz, Paula T.
    Williams, David W.
    Feldman, Peter D.
    Witcher, Jennifer W.
    Buitelaar, Jan K.
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2007, 19 (02) : 222 - 223
  • [6] CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD
    Trzepacz, Paula T.
    Williams, David W.
    Feldman, Peter D.
    Wrishko, Rebecca E.
    Witcher, Jennifer W.
    Buitelaar, Jan K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 (02) : 79 - 86
  • [7] Influence of CYP2D6 Metabolizer Status on Risperidone and Paliperidone Tolerability in Children and Adolescents
    Kanu, Amarachi A.
    Johnston, Michelle M.
    Poweleit, Ethan A.
    Vaughn, Samuel E.
    Strawn, Jeffrey R.
    Ramsey, Laura B.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2024, 34 (01) : 34 - 41
  • [8] Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion
    Güzey, C
    Nordström, Å
    Spigset, O
    THERAPEUTIC DRUG MONITORING, 2002, 24 (03) : 436 - 437
  • [9] Impact of CYP2D6 metabolizer phenotype on the safety profile of paliperidone ER
    Dunbar, Fiona
    Chue, Pierre
    Fu, Dong-Jing
    Huang, Qiqing
    Franc, Monique-Andree
    Cohen, Nadine
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 83S - 83S
  • [10] CYP2C19 METABOLIZER STATUS PREDICTS ESCITALOPRAM PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS
    Vaughn, Sam
    Poweleit, Ethan
    Desta, Zeruesenay
    Strawn, Jeffrey
    Ramsey, Laura
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2021, 60 (10): : S215 - S215
12345